Zurueck zur Suche

Reporte zur Charge NP33H

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

5Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CA 2 MN 1 DE 1 MD 1

VAERS 962994

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge np33h

schwer
Staat
MN
Alter
53,0
Geschlecht
M
Eingang
21.01.2021
Impfdatum
21.01.2021
Beginn
21.01.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Syncope

Symptomtext

The patient fainted about 2-3 minutes after injection

Weitere VAERSDATA-Felder
Praegender Schweregrund
Syncope
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1470337

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge NP33H

mild
Staat
CA
Alter
60,0
Geschlecht
F
Eingang
14.07.2021
Impfdatum
18.02.2021
Beginn
18.02.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Arthralgia Chills Immediate post-injection reaction Monoplegia Nausea

Symptomtext

Pt. states after receiving the Shingrix 02/18/2021, started to experience immediate pain in the shoulder in doctor?s office. Left arm paralyzed for 2 days from the shoulder to elbow, extreme chills, nauseous subsiding estimated 02/21/2021.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Arthralgia
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
N/A
Vorgeschichte
Asthma
Andere Medikamente
N/A
Allergien
Perfume
Vorherige Impfungen
-

VAERS 1280242

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge np33h

mild
Staat
DE
Alter
65,0
Geschlecht
F
Eingang
02.05.2021
Impfdatum
17.08.2020
Beginn
17.08.2020
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: nein
Allergy test Biopsy skin Blood test Burning sensation Computerised tomogram Pain in extremity

Symptomtext

Vaccine given at 1030 am. At approx 5pm patient started noticing burning of both hands and feet along with body chills. Next day burning and chills were absent however patient had 101.2 fever lasting 1 day. Approximately 10 days later burning in bilateral hands and feet returned with worsening symptoms calling GP on Sept 4th 2002. GP instructed patient to make an appointment with Neurology. Patient was in extreme pain in hands and feet resulting in ER visit on 9/11/20. ER did CT scan and blood work with no notable findings. Patient went to neurology on 9/16/20 and was referred to an allergy immunologist who at appointment ran test with no clinical findings. Patient went to GP on 10/20/2020 and MD had patient stop Crestor CoQ10. She was put on b12 and Folate. Patient also stopped celexa and started Duloxetine and take gabapentin as needed up to 3 times daily. This combination helped burning of hands and feet. Patient was referred to Neurology and was seen on 3/15/2021. Workup done including 3 punch biopsy. Neurology is trying to determine if neuropathy is from Shingrix due to onset of symptoms, or from pre diabetes.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pain in extremity
Hospital-Tage
-
Labordaten
see above
Aktuelle Erkrankungen
-
Vorgeschichte
high chol high bp
Andere Medikamente
enalapril 5mg rosutatin 10mg mometasone ointment citalopram premarin vaginal cream
Allergien
bactrim fosamax ic contrast monastatin hydrocortisone cream macrobid thimerisol
Vorherige Impfungen
local reaction from pneumonia

VAERS 1093836

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge NP33H

mild
Staat
MD
Alter
63,0
Geschlecht
F
Eingang
12.03.2021
Impfdatum
22.07.2020
Beginn
-
Tage bis Beginn
-
Dosis
1
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Pain Pyrexia

Symptomtext

Fever; pain; This case was reported by a nurse via call center representative and described the occurrence of fever in a 63-year-old female patient who received Herpes zoster (Shingrix) (batch number NP33H, expiry date 8th April 2022) for prophylaxis. Previously administered products included ZOSTAVAX (received in the past.). On 22nd July 2020, the patient received the 1st dose of Shingrix. On an unknown date, less than 6 months after receiving Shingrix, the patient experienced fever and pain. On an unknown date, the outcome of the fever was unknown and the outcome of the pain was recovered/resolved. It was unknown if the reporter considered the fever and pain to be related to Shingrix. Additional details were provided as follows: After receiving 1st dose of Shingrix, the patient experienced fever and pain for 33 hours. The nurse was looking for more medical information about side effects after Shingrix. The patient was worried about having second dose and feeling worst. The reporter consent to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pain
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1284644

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge NP33H

gering
Staat
CA
Alter
62,0
Geschlecht
F
Eingang
04.05.2021
Impfdatum
28.04.2021
Beginn
28.04.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration

Symptomtext

2nd dose of shingrix late.1st dose of shingrix was on 09/05/2019 and 2nd dose on 4/28/2021; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 62-year-old female patient who received Herpes zoster (Shingrix) (batch number NP33H, expiry date 8th April 2022) for prophylaxis. Previously administered products included Shingrix (received 1st dose in 5th September 2019). On 28th April 2021, the patient received the 2nd dose of Shingrix. On 28th April 2021, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown. Additional details were reported as follows: The patient received the 2nd dose of Shingrix later than the recommended interval, which led to lengthening of the vaccination schedule. The reporter enquired about revaccination. The reporter consented to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-